First Trust Nasdaq Pharmaceuticals ETF
FTXH
26 hedge funds and large institutions have $11.9M invested in First Trust Nasdaq Pharmaceuticals ETF in 2025 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 2 closing their positions.
350% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 2
69% more capital invested
Capital invested by funds: $7.04M → $11.9M (+$4.87M)
37% more funds holding
Funds holding: 19 → 26 (+7)
10.73% more ownership
Funds ownership: 44.87% → 55.6% (+11%)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
+$1.31M |
| 2 |
MIM
Marshall Investment Management
Littleton,
Colorado
|
+$1.3M |
| 3 |
OMC
Old Mission Capital
Chicago,
Illinois
|
+$499K |
| 4 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$354K |
| 5 |
OIA
OneDigital Investment Advisors
Overland Park,
Kansas
|
+$304K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$588K |
| 2 |
WFA
WMG Financial Advisors
Knoxville,
Tennessee
|
-$306K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$145K |
| 4 |
SC
Steph & Co
Marinette,
Wisconsin
|
-$142K |
| 5 |
SWP
Stratos Wealth Partners
Beachwood,
Ohio
|
-$13.3K |
FTXH Hedge Fund Activity: Q4 2025 in Review
26 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in First Trust Nasdaq Pharmaceuticals ETF (FTXH) for Q4 2025, worth a combined $11.9M — up 69% from $7.04M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new FTXH positions and 2 closed out — a net gain of 7 holders — while 6 added to existing stakes and 7 trimmed.
The largest buyer was LPL Financial, adding an estimated $1.31M. The largest seller was Goldman Sachs, cutting an estimated $588K.
- 26 institutional investors held First Trust Nasdaq Pharmaceuticals ETF (FTXH) as of Q4 2025, up from 19 in Q3 2025.
- Funds reported $11.9M of First Trust Nasdaq Pharmaceuticals ETF stock for Q4 2025, up 69% quarter-over-quarter.
- 9 funds opened new First Trust Nasdaq Pharmaceuticals ETF positions in Q4 2025 and 2 closed out, a net change of +7 holders.
- The largest First Trust Nasdaq Pharmaceuticals ETF buyer in Q4 2025 was LPL Financial, an estimated $1.31M added.
- The largest First Trust Nasdaq Pharmaceuticals ETF seller in Q4 2025 was Goldman Sachs, an estimated $588K sold.
Based on aggregated 13F filings for Q4 2025.